BioLife recently partnered with HemaCare and BioInsights to create our latest Biopreservation Best Practices White Paper. See for yourself how critical starting material quality is for CAR-T and other cell manufacturing and learn how to best optimize your biopreservation methods to follow best practices.
Read More
BioLife Solutions Inc. today announced that Michael Rice, CEO, and Roderick de Greef, CFO, will be attending and presenting at the 2018 BIO International Convention, June 4 – 7, 2018, at the Boston Convention and Exhibition Center. The corporate presentation is scheduled at 4:30PM on Monday, June 4th in theater 4. Investor and partner attendees interested to meet…
Read More
BioLife maintains an evidence page on our corporate website at biolifesolutions.com with links to presentations, journal articles, abstracts and posters citing the biopreservation efficacy of CryoStor and HypoThermosol. These citation “evidence” pieces total over 345 strong and is constantly growing! Individual evidence citations (journal articles, abstracts, and posters citing our products) are searchable by title and…
Read More
FDA approvals for Novartis’ Kymriah™ and Kite’s Yescarta™ in 2017 ushered in a new era of medical treatments using cell and gene therapies. Transporting these high value, unique, and often irreplaceable autologous cells from point of collection, to processing center, and back to the patient for administration calls for a paradigm change to the traditional…
Read More
On April 9, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, (“BioLife” or the “Company”), announced that Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second…
Read More
On April 2, 2018, BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary revenue for the three months ended March 31, 2018. First quarter 2018 preliminary revenue from sales of BioLife’s proprietary CryoStor® and HypoThermosol® biopreservation media products reached $3.8 million,…
Read More
12 Additional Pending Patent Applications Submitted for evo® Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application On March 26, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologies, the leading developer of smart,…
Read More
On March 20, 2018 Dr. Brian Hawkins, Scientific Applications Director, will be presenting a poster entitled, “The prats and pitfalls of assessing cell viability after cryopreservation,” at the 2018 PDA Annual Meeting in Orlando, FL. The poster describes how common methods of determining cell viability under normal conditions are inconsistent and inaccurately represent cell health…
Read More On March 13, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that the performance of its proprietary, cGMP CryoStor cell freeze media was reported in the journal Laboratory Investigation. In multiple comparisons of preservation efficacy of patient-derived xenograft (PDX) tumors,…
Read MoreWang X, Popplewell L, Wagner J, Naranjo A, Blanchard M, Mott M, Norris A, Wong C, Urak R, Chang W, Khaled S, Siddiqi T, Budde L, Xu J, Chang B, Gidwaney N, Thomas S, Cooper L, Riddell S, Brown C, Jensen M, Forman S. Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following…
Read More